Skip to content

Salarius

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Programs
    • Targeted Protein Inhibition
    • Targeted Protein Degradation
    • Pipeline
    • Publications Review
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
      • Corporate Governance
      • Committee Composition
    • Press Releases
    • In The News
    • Financial Reports
      • Annual Reports
      • Quarterly & Other Reports
      • Tax Documents
    • SEC Filings
    • Events & Presentations
    • Investor Resources
      • Investor FAQs
      • Information Request
      • E-mail Alerts
      • Contact IR
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
    • Analyst Coverage
  • Contact Us
Search

Our Programs

  • Targeted Protein Inhibition
  • Targeted Protein Degradation
  • Pipeline
  • Publications Review
  • Clinical Trials

Publications Review

Targeted Protein Degradation

NATURE REVIEWS: CLINICAL ONCOLOGY

Protein degraders enter the clinic — a new approach to cancer therapy

BIOCHEMISTRY

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic

NATURE REVIEWS: DRUG DISCOVERY

Targeted protein degraders crowd into the clinic

NATURE CHEMICAL BIOLOGY

Molecular glue concept solidifies

LSD1’s Role in Cancer

National Library of Medicine

Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases

Nature Immunology

Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis

Cell

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

ACS chemical biology

Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and-independent manners.

More

SP-2577 and Analogs

National Library of Medicine

LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway

National Library of Medicine

LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level

National Library of Medicine

SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling

American Association for Cancer Research

The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

More

Salarius

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Programs
    • Targeted Protein Inhibition
    • Targeted Protein Degradation
    • Pipeline
    • Publications Review
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
    • Press Releases
    • In The News
    • Financial Reports
    • SEC Filings
    • Events & Presentations
    • Investor Resources
    • Stock Information
    • Analyst Coverage
  • Contact Us
  • Like Us on Facebook
  • Follow Us on Twitter
  • Connect on LinkedIn
© 2023 Salarius Pharmaceuticals, Inc. All Rights Reserved. Privacy and Terms of Use